A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
Status:
Not yet recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK112
(anti-PD-1 and VEGF bispecific antibody) combined with AK117#AntiCD47 Antibody# in advanced
malignant tumors